Skip to main content

Table 2 Changes in protein expression of various biomarkers and their mutational status and progression free survival

From: Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib

  Mutational status of tumor PFS (Days) PI3K (% change) pPI3K (% change) IGF1R (% change) pMEK (% change) cMET (% change) pERK (% change) pAKT (% change)
  BRAF 385 -99.5 -97.1 -93.6 - -72.3 - -83.9
  Wt 275 -46.3 -75.3 -61 -92.9 -75.8 -96.8 -90.4
  KRAS + PIK3CA 274 -39.7 54.9 0 0 378.7 1570 2653.9
  Wt 252 -97.7 0 -59.3 0 -86 -93.3 -61.5
  Wt 484 -86 -86.8 -95.3 0 -97.1 -87.5 210
  Wt 236 -63.2 -96.7 -99.4 -94.2 -73.1 -98.1 -98.7
  Wt 109 -99.8 0 59.1 0 1261 30.6 -64.3
  BRAF 106 483.3 97.3 1630 0 473.3 540 975
  NRAS 106 -92.7 -96.8 -97.2 -92.5 -93.5 -99 -64.3
  KRAS + PIK3CA 105 -99.9 0 0 0 1864.5 0 -81.8
  KRAS 48 36020 -38.3 38.6 730 561.7 1490 2653.9
  KRAS 47 180 770 7.6 -37.1 324.8 1.3 571
  BRAF + KRAS 49 159.7 -96.5 12.7 -94.2 20 -81.6 -97.5
  PIK3CA + NRAS 49 -85.7 -99.6 -99.9 -97.6 -86.4 -96.2 -81.3
*Test of null hypothesis P value    0.01 0.50 0.12 0.57 0.07 0.53 0.70
  1. Wt – Wild-type.
  2. Negative % change reflects downregulation; positive % change reflects upregulation.
  3. *Mann Whitney U test (2-tailed) of PFS between patient populations with upregulated or downregulated protein expression.